SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2018 / Cilt: 4 - Sayı: 3

Efficacy of Antioxidant Treatment on the Symptoms of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome Category IIIA

Kronik Prostatit Kategori Tip IIIA / Kronik Pelvik Ağrı Sendromlu Hastalarda Antioksidan Tedavinin Semptomlar Üzerine Etkisi

Erhan ATEŞ
İlter ALKAN
Pages
215–219
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A reduction of the NIH-CPSI total score by ≥25% after the treatment was accepted as an improvement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the effect of antioxidant treatment on the symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome CP/CPPS category IIIA.Material and Methods: We retrospectively evaluated the data of patients with chronic prostatitis/chronic pelvic pain syndrome category IIIA who were treated by Progeny- M®, an antioxidant agent, between October 2016 and December 2017.
📊
Key Findings & Data:The pretreatment and posttreatment symptoms were assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index NIH-CPSI .
💡
Conclusion & Impact:A reduction of the NIH-CPSI total score by ≥25% after the treatment was accepted as an improvement.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Kronik prostatit · Kronik pelvik ağrı sendromu · Antioksidan tedavi

Abstract

Objective: The aim of this study was to evaluate the effect of antioxidant treatment on the symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome CP/CPPS category IIIA.Material and Methods: We retrospectively evaluated the data of patients with chronic prostatitis/chronic pelvic pain syndrome category IIIA who were treated by Progeny- M®, an antioxidant agent, between October 2016 and December 2017. The pretreatment and posttreatment symptoms were assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index NIH-CPSI . A reduction of the NIH-CPSI total score by ≥25% after the treatment was accepted as an improvement. A value of P

Özet

Amaç: Çalışmanın amacı kronik prostatit kategori tip IIIA / kronik pelvik ağrı sendromlu KP/KPAS hastalarda antioksidan tedavinin semptomlar üzerine etkisinin değerlendirilmesidir.Gereç ve Yöntemler: Ekim 2016 ile Aralık 2017 arasında antioksidan ajan olan Progeny-M® ile tedavi edilen KP/KPAS kategori IIIA hastaların verileri retrospektif olarak değerlendirildi. Tedavi öncesi ve tedavi sonrası semptomların değerlendirilmesinde National Institute of Health- Kronik Prostatit Semptom İndeksi NIH-KPSİ kullanıldı. Tedaviden sonra NIH-KPSİ toplam skorunda %25’ten fazla azalma tedaviye yanıt olarak kabul edildi. P

🔖

Cite This Article

ATEŞ, E., ALKAN, İ. (2022). Efficacy of Antioxidant Treatment on the Symptoms of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome Category IIIA. Akdeniz Tıp Dergisi, Cilt: 4 - Sayı: 3, 215–219. https://ajindex.com/articles/434435

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31 Suppl. 1: 85-90.
  2. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236-7. Nickel JC: Prostatitis syndromes: An update for urologic practice. Can J Urol 2000;7: 1091-8.
  3. Schaeffer AJ, Datta NS, Fowler JE Jr, Krieger JN, Litwin MS, Nadler RB. Chronic Prostatitis Collaborative Research N. 2002 Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology 2002; 60:1-4.
  4. Schaeffer AJ, Knauss JS, Landis JR, Propert KJ, Alexander RB, Litwin MS, Nyberg LM. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. Journal of Urology 2002; 168:1048-53.
  5. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. J Urology 1999; 162:369-75.
  6. Breser ML, Salazar FC, Rivero VE, Motrich RD. Immunological mechanisms underlying chronic pelvic pain and prostate in chronic pelvic pain syndrome. Front Immunol 2017; 8:898. Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, Steinhoff G, Brock G, Patrick AB, Flax S, Goldfarb B, Palmer BW, Zadra J. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: A randomized placebo-controlled multicenter trial. Urology 2003;62(4):614-7.
  7. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/ chronic pelvic pain syndrome with tamsulosin: A randomized double blind trial. J Urol 2004;171(4):1594-7.
  8. Zhao WP, Zhang ZG, Li XD, Yu D, Rui XF, Li GH, Ding GQ. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Braz J Med Biol Res 2009;42(10):963-7.
  9. Rugendorff EW, Weidner W, Ebeling L, Buck AC. Results of treatment with pollen extract (cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993;71: 433-8.
  10. Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl 2000;21:669-75.
  11. Pasqualotto FF, Sharma RK, Potts JM, Nelson DR, Thomas AJ, Agarwal A. Seminal oxidative stress in patients with chro